Product Description
Mechanisms of Action: ER Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Canada | Colombia | Germany | India | Ireland | New Zealand | Pakistan | Peru | Poland | Portugal | Slovenia | Taiwan
Approved Indications: None
Known Adverse Events: None
Company: PrimeVax Immuno-Oncology
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 5
Highest Development Phases
Phase 3: Adenocarcinoma|Esophageal Cancer|Gastrointestinal Cancer
Phase 2: Non-Small-Cell Lung Cancer|Prostate Cancer
Phase 1: Melanoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
RC48-C035 | P3 |
Recruiting |
Adenocarcinoma|Esophageal Cancer|Gastrointestinal Cancer |
2026-12-01 |
|
RC48-C021 | P2 |
Not yet recruiting |
Non-Small-Cell Lung Cancer |
2025-12-01 |
|
RC48-C034 | P2 |
Recruiting |
Prostate Cancer |
2025-12-01 |
|
PV001-001 (Arm 2) | P1 |
Not yet recruiting |
Melanoma |
2024-09-30 |
27% |